Ernexa Therapeutics Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
ERNA$2.01-2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| For the three months ended March 31, | |||
|---|---|---|---|
| 2026 · 2025 | |||
| Cash flows from operating activities: | |||
| Net loss | $(5,506) | $(8,202) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation and amortization | 8 | 18 | |
| Stock-based compensation | 309 | 502 | |
| Amortization of right-of-use asset | 78 | 51 | |
| Impairment of goodwill | 2,044 | - | |
| Issuance of common stock to consultant for services | 96 | 45 | |
| Accrued interest expense | - | 6 | |
| Forward sales contract expense | - | 5,335 | |
| Change in fair value of warrant liabilities | - | (1) | |
| Changes in operating assets and liabilities: | |||
| Other receivables | - | 281 | |
| Prepaid expenses and other current assets | (320) | 49 | |
| Other non-current assets | - | 1 | |
| Accounts payable and accrued expenses | 759 | (98) | |
| Operating lease liability | (75) | (52) | |
| Due from related party | 750 | - | |
| Due to related party | (500) | - | |
| Other liabilities | 93 | - | |
| Net cash used in operating activities | (2,264) | (2,065) | |
| Cash flows from investing activities: | |||
| Purchase of property and equipment | (2) | - | |
| Net cash used in investing activities | (2) | - | |
| Cash flows from financing activities: | |||
| Gross proceeds received from the sale of common stock, prefunded warrants and Milestone Warrants in public offering | 10,480 | - | |
| Fees related to public offering | (939) | - | |
| Proceeds received from notes payable | - | 2,250 | |
| Gross proceeds received from the exercise of prefunded warrants | 20 | 4 | |
| Fee related to the exercise of prefunded warrants from public offering | (2) | - | |
| Net cash provided by financing activities | 9,559 | 2,254 | |
| Net increase in cash | 7,293 | 189 | |
| Cash at beginning of period | 1,884 | 1,729 | |
| Cash at end of period | $9,177 | $1,918 | |
| Supplemental disclosure of non-cash investing and financing activities: | |||
| Remeasurment of ROU asset and lease liability | $26 | $ | - |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.